Predictive value of serum biomarkers for survival in melanoma: a systematic review and meta-analysis.
Blood tests detecting tumor DNA and standard markers like LDH predict melanoma survival, though routine use needs clearer guidelines for real-world practice.
This meta-analysis confirms strong prognostic utility of ctDNA and several serum biomarkers in melanoma, with ctDNA showing among the highest hazard ratios for death. LDH remains cost-effective and reliable, while NLR may complement prognostic assessment in checkpoint inhibitor-treated patients, though routine ctDNA implementation requires further clinical evaluation.
What the study was
- Study design
- Systematic review and meta-analysis (PRISMA, PROSPERO: CRD42023486532)
- Population
- Melanoma patients; multiple included studies
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- Scientific Reports
Why it surfaced
Well-designed PRISMA/PROSPERO meta-analysis confirming prognostic value of multiple serum biomarkers in melanoma, with ctDNA showing strong signal. Solidifies the ctDNA monitoring evidence base. Sci Rep publication; score limited by consolidation of existing knowledge rather than novel discovery.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.